Print

Purpose

This study will determine (i) the magnitude of immediate and sustained effects of a current clinical standard interactive computer attention processing training (APT) when combined with intermittent theta burst stimulation (iTBS), a type of repetitive transcranial magnetic stimulation and (ii) determine how APT + iTBS changes the neurocognitive system of attention in individuals with persistent attention deficits related to mTBI +/- PTSD.

Conditions

Eligibility

Eligible Ages
Between 18 Years and 80 Years
Eligible Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • At least 18 years of age and no older than 80 years of age - 3 months post exposure to mTBI event - Have a history of mTBI with PTSD OR mTBI without PTSD as defined by formalized measures to classify mTBI based on the Symptom Attribution and Classification Algorithm (SACA) and the PTSD Module L of the SCID - Endorse at least moderate severity on at least one of the four cognitive complaints in the Neurobehavioral Symptom Inventory

Exclusion Criteria

  • Participating in another research study - Non-fluent in English (speaking and reading) - History of epilepsy pre-injury - Receiving antiepileptic treatment for documented active seizures in the past 6 months - Taking medications that lower seizure threshold including antipsychotics, trazodone and tramadol - History of surgery on blood vessels in brain and/or valves of the heart - History of brain hemorrhage, neurovascular conditions and neurodegenerative disorders - History or current diagnosis of psychotic spectrum disorders (i.e. bipolar, schizophrenia) - Significant heart disease as determined by physician review of medical chart - Pregnant at time of enrollment or any time during study participation - MRI or TMS/iTBS contraindications such as claustrophobia, metal in eyes/face or brain - Cardiac pacemakers/defibrillators, cochlear implants, nerve stimulators, intracranial metal clips - Diagnosis of moderate or severe TBI (loss of consciousness > 30 minutes, alteration of consciousness > 24 hours, post traumatic amnesia or neuropsychological testing results - Prescribed dosage of mental health medications have been altered within the month preceding study screening. Any participant whose mental health medication(s) has/have changed, within 30 days of study screening. The following are considered a medication change: the addition of or discontinuation of medication, a change in the dose or dosage (daily amount) of medication. - Taking prescribed CNS stimulants and choosing to not stop these medications during study participation - Taking prescribed CNS stimulants and choosing to not stop these medications during study participation - Testing positive for opiates and do not have a prescription for opiates. If on prescription opiates and taking more than the equivalent of 200 mg of morphine per day. - Questionably valid test performance as indicated by a score of ≤ 85% on the Immediate Recognition, Delayed Recognition or Consistency Scales of the Medical Symptom Validity Test (MSVT) and clinical determination of questionable performance validity by a neuropsychologist on the research team - Actively suicidal as evidenced by plan to harm or recent attempt communicated on the Structured Clinical Interview for DSM-V (SCID-5). - Increased Intracranial Pressure (ICP) as evidenced through a funduscopic evaluation or on the baseline MRI scan. - Moderate or severe cannabis use disorder defined by ≥ 4 symptoms on the SCID-5 - Severe alcohol use disorder defined by ≥ 6 symptoms on the SCID-5 - Baseline systolic BP greater or equal to 170

Study Design

Phase
N/A
Study Type
Interventional
Allocation
Randomized
Intervention Model
Factorial Assignment
Primary Purpose
Treatment
Masking
Triple (Participant, Investigator, Outcomes Assessor)

Arm Groups

ArmDescriptionAssigned Intervention
Experimental
real APT+ real iTBS 		real APT+ real iTBS included 30 1-hour treatment sessions will be provided 3/week. Sessions will be conducted for 10 weeks. APT-III is a computer based cognitive training program. iTMS will be applied at 5Hz rate; each burst consists of 3 pulses delivered at 50Hz rate. The bursts are applied for 2s with 8s inter-burst-intervals, for a total of 600 pulses. The total stimulation time per session is approximately 192s (~ 3 minutes). Participants randomized to active iTBS will receive stimulation at the right dorsolateral prefrontal cortex at 80% active motor threshold .
  • Device: real iTBS
    Intermittent Theta Burst Stimulation (iTBS) is a form of repetitive transcranial magnetic stimulation (rTMS), which uses short magnetic field pulses applied to the scalp to induce currents in the underlying brain. iTBS will be delivered with the Magventure MagProX100 with MagOption stimulator and Magpro Cool Coil B65 A/P. The Magpro Cool Coil B65 A/P can be switched to active or placebo (A/P).
    Other names:
    • intermittent Theta Burst Stimulation
  • Behavioral: real APT
    APT-III is an attention processing training program
    Other names:
    • Attention Processing Training-III
Active Comparator
real APT + placebo iTBS 		30 1-hour treatment sessions will be provided 3/week. Sessions will be conducted for 10 weeks. APT-III is a computer based cognitive training program. Participants randomized to placebo iTBS will not receive any iTBS stimulation.
  • Behavioral: real APT
    APT-III is an attention processing training program
    Other names:
    • Attention Processing Training-III
  • Device: placebo iTBS
    delivered with the Magventure MagProX100 with MagOption stimulator and Magpro Cool Coil B65 A/P. The Magpro Cool Coil B65 A/P can be switched to active or placebo (A/P).
    Other names:
    • sham intermittent Theta Burst Stimulation
Active Comparator
placebo APT+ real iTBS 		30 1-hour treatment sessions will be provided 3/week. Sessions will be conducted for 10 weeks. Placebo APT-III is a computer based active control cognitive training program. Bursts of TMS pulses will be applied at 5Hz rate; each burst consists of 3 pulses delivered at 50Hz rate. The bursts are applied for 2s with 8s inter-burst-intervals, for a total of 600 pulses. The total stimulation time per session is approximately 192s (~ 3 minutes). Participants randomized to active iTBS will receive stimulation at the right DLPFC at 80% active motor threshold .
  • Device: real iTBS
    Intermittent Theta Burst Stimulation (iTBS) is a form of repetitive transcranial magnetic stimulation (rTMS), which uses short magnetic field pulses applied to the scalp to induce currents in the underlying brain. iTBS will be delivered with the Magventure MagProX100 with MagOption stimulator and Magpro Cool Coil B65 A/P. The Magpro Cool Coil B65 A/P can be switched to active or placebo (A/P).
    Other names:
    • intermittent Theta Burst Stimulation
  • Behavioral: placebo APT
    computerized cognitive training
    Other names:
    • Active Control APT
Active Comparator
placebo APT+ placebo iTBS 		30 1-hour treatment sessions will be provided 3/week. Sessions will be conducted for 10 weeks. Placebo APT-III is a computer based active control cognitive training program. Participants randomized to placebo iTBS will not receive any iTBS stimulation.
  • Behavioral: placebo APT
    computerized cognitive training
    Other names:
    • Active Control APT
  • Device: placebo iTBS
    delivered with the Magventure MagProX100 with MagOption stimulator and Magpro Cool Coil B65 A/P. The Magpro Cool Coil B65 A/P can be switched to active or placebo (A/P).
    Other names:
    • sham intermittent Theta Burst Stimulation

Recruiting Locations

Northwestern University
Chicago 4887398, Illinois 4896861 60141
Contact:
Katie Kestner, PT
708-878-0578
ckestner@sralab.org

Moody Neurorehabilitation Institute
Houston 4699066, Texas 4736286 77058
Contact:
Meredith Brown, PT
409-797-1468
mbrown@moodyneuro.org

More Details

Status
Recruiting
Sponsor
Northwestern University

Study Contact

Catherine M Kestner
708-878-0578
ckestner@sralab.org

Notice

Study information shown on this site is derived from ClinicalTrials.gov (a public registry operated by the National Institutes of Health). The listing of studies provided is not certain to be all studies for which you might be eligible. Furthermore, study eligibility requirements can be difficult to understand and may change over time, so it is wise to speak with your medical care provider and individual research study teams when making decisions related to participation.